glp 1 tx GLP-1 Hunger – North Texas Wellness Center 30-Day GLP-1 Strength Training Program

Semaglutide specifically showed an average weight loss of 9.2 percent in patients with overweight and obesity over 68 weeks in SUSTAIN 12

long-term health and aging-related outcomes

The FDAs accelerated approval was supported by data from the Phase II MagnetisMM-3 study, which found that in heavily pretreated RRMM patients who had not yet received BCMA-directed therapy, Elrexfio had an overall response rate of 58%, with around 82% of responders maintaining improvements for at least nine months

Best For: Healing and recovery, especially for active individuals or those with chronic injuries

These findings are consistent with data accessed January 12, 2026